Prs17 - Budget Impact Analysis of the Use of Umeclidinium Bromide/Vilanterol 62.5/25 MCG in the Treatment of Chronic Obstructive Pulmonary Disease in Spain
Value in Health- United Kingdom
doi 10.1016/j.jval.2018.09.2411
Full Text
Abstract
Available in
Date
October 1, 2018
Authors
Publisher
Elsevier BV